Investor Presentaiton

Investment Highlights TC BIOPHARM Platform Technology - Allogenic Gamma Delta T-Cell (off-the-shelf) Cell Therapy for Oncology Company Focused on ACHIEVE Interim Data Generation Clinical Data 2H 2024 Multiple Partnership Opportunities in Combination Trials Using TCB-008 in Discussion Platform Expansion into New Indications with QMUL Collaboration Gained FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia Extended Cash Runway Via Decreased Headcount 3

View entire presentation